1. Home
  2. ZVIA vs ENGN Comparison

ZVIA vs ENGN Comparison

Compare ZVIA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevia PBC

ZVIA

Zevia PBC

HOLD

Current Price

$1.50

Market Cap

111.3M

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.65

Market Cap

115.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZVIA
ENGN
Founded
2007
1999
Country
United States
Canada
Employees
N/A
82
Industry
Beverages (Production/Distribution)
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
111.3M
115.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ZVIA
ENGN
Price
$1.50
$1.65
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
$4.93
$21.08
AVG Volume (30 Days)
1.2M
1.4M
Earning Date
05-06-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
55.88
N/A
EPS
N/A
N/A
Revenue
$161,259,000.00
N/A
Revenue This Year
$8.30
N/A
Revenue Next Year
$6.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.01
N/A
52 Week Low
$1.11
$1.40
52 Week High
$3.66
$12.25

Technical Indicators

Market Signals
Indicator
ZVIA
ENGN
Relative Strength Index (RSI) 54.65 30.44
Support Level $1.13 $1.40
Resistance Level $1.53 $1.87
Average True Range (ATR) 0.13 0.09
MACD -0.02 0.20
Stochastic Oscillator 31.78 26.67

Price Performance

Historical Comparison
ZVIA
ENGN

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: